Bridget E. Bunner

Array ( [id] => 11082271 [patent_doc_number] => 20160279236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'USE OF RAPAMYCIN AS VACCINE ADJUVANT AND PREPARATION METHOD THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/907769 [patent_app_country] => US [patent_app_date] => 2014-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6094 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14907769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812016 [patent_doc_number] => 20150023961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'METHODS OF MODULATING IMMUNOLOGICAL RESPONSES BY ADMINISTERING TRUNCATED BAFF RECEPTORS' [patent_app_type] => utility [patent_app_number] => 14/444139 [patent_app_country] => US [patent_app_date] => 2014-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 11611 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14444139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018093 [patent_doc_number] => 20160215046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY' [patent_app_type] => utility [patent_app_number] => 14/900024 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 10187 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14900024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10815327 [patent_doc_number] => 20160161487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'CONTROL OF UTERINE CONTRACTIONS' [patent_app_type] => utility [patent_app_number] => 14/905875 [patent_app_country] => US [patent_app_date] => 2014-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14884 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14905875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10974149 [patent_doc_number] => 20140377184 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'Methods and Compositions Related to Targeting Tumors and Wounds' [patent_app_type] => utility [patent_app_number] => 14/331048 [patent_app_country] => US [patent_app_date] => 2014-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24233 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14331048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551259 [patent_doc_number] => 10344072 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Soluble CD33 for treating myelodysplastic syndromes (MDS) [patent_app_type] => utility [patent_app_number] => 14/902719 [patent_app_country] => US [patent_app_date] => 2014-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 79 [patent_no_of_words] => 23098 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100895 [patent_doc_number] => 20160297865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'METHODS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/902966 [patent_app_country] => US [patent_app_date] => 2014-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18687 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14902966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10887749 [patent_doc_number] => 08911741 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-12-16 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 14/322581 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13423 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10911763 [patent_doc_number] => 20140314781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/322565 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13605 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10706869 [patent_doc_number] => 20160053016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-25 [patent_title] => 'COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 14/308371 [patent_app_country] => US [patent_app_date] => 2014-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 35854 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14308371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219467 [patent_doc_number] => 20150104461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'ANTI-NOTCH2 NRR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/298488 [patent_app_country] => US [patent_app_date] => 2014-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 51120 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14298488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10219467 [patent_doc_number] => 20150104461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-16 [patent_title] => 'ANTI-NOTCH2 NRR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/298488 [patent_app_country] => US [patent_app_date] => 2014-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 51120 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14298488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9798626 [patent_doc_number] => 20150010570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR' [patent_app_type] => utility [patent_app_number] => 14/295692 [patent_app_country] => US [patent_app_date] => 2014-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6943 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14295692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11263291 [patent_doc_number] => 09487579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Methods and compositions for modulation of blood-neural barrier' [patent_app_type] => utility [patent_app_number] => 14/282808 [patent_app_country] => US [patent_app_date] => 2014-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 17715 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14282808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10790116 [patent_doc_number] => 20160136272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-19 [patent_title] => 'METHODS FOR RESTORING CORTICOSTEROID SENSITIVITY' [patent_app_type] => utility [patent_app_number] => 14/890921 [patent_app_country] => US [patent_app_date] => 2014-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 36732 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14890921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514313 [patent_doc_number] => 20170081387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'FUSION PROTEIN INHIBITING TACI-BAFF COMPLEX FORMATION AND PREPARATION METHOD THEREFOR AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/310703 [patent_app_country] => US [patent_app_date] => 2014-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9223 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15310703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9792185 [patent_doc_number] => 20150004129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => 'BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/264402 [patent_app_country] => US [patent_app_date] => 2014-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 18606 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14264402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10635675 [patent_doc_number] => 09353168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Method of reducing cell death by administering a paracrine factor derived from a mesenchymal stem cell' [patent_app_type] => utility [patent_app_number] => 14/256174 [patent_app_country] => US [patent_app_date] => 2014-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16558 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14256174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554815 [patent_doc_number] => 09279012 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell' [patent_app_type] => utility [patent_app_number] => 14/256169 [patent_app_country] => US [patent_app_date] => 2014-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16605 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14256169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11296741 [patent_doc_number] => 09504733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-29 [patent_title] => 'Regulation of energy metabolism and obesity by modulating a proliferation-inducing ligand (APRIL) or APRIL signaling' [patent_app_type] => utility [patent_app_number] => 14/252498 [patent_app_country] => US [patent_app_date] => 2014-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 20 [patent_no_of_words] => 11610 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14252498 [rel_patent_id] =>[rel_patent_doc_number] =>)